EPM2A anticorps (Internal Region)
Aperçu rapide pour EPM2A anticorps (Internal Region) (ABIN335145)
Antigène
Voir toutes EPM2A AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Épitope
- Internal Region
-
Fonction
- Laforin (isoform a)
-
Séquence
- EATGHTNEMK HTTD
-
Specificité
- This antibody is expected to recognize isoform a (NP_005661.1) only.
-
Réactivité croisée
- Boeuf (Vache), Chien, Humain, Souris, Rat
-
Purification
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
-
Immunogène
- Peptide with sequence C-EATGHTNEMKHTTD, from the internal region of the protein sequence according to NP_005661.1.
-
Isotype
- IgG
-
-
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibody
EPM2A Reactivité: Humain WB, ELISA Hôte: Souris Monoclonal 6C6 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (C-Term) antibodyEPM2A Reactivité: Humain WB, ICC, IF, IHC (p) Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331), (Isoform 9) antibodyEPM2A Reactivité: Humain WB, ELISA, IHC, IF Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) antibodyEPM2A Reactivité: Humain, Rat, Souris ELISA, IHC Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibodyEPM2A Reactivité: Humain WB, IP Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reactivité: Humain ELISA, IHC Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 80-130) antibodyEPM2A Reactivité: Humain, Boeuf (Vache) WB, IHC, IHC (p) Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibodyEPM2A Reactivité: Humain WB, ELISA Hôte: Souris Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (Internal Region) antibody (Biotin)Verified EPM2A Reactivité: Humain WB, ELISA, IHC Hôte: Chèvre Polyclonal Biotin
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reactivité: Humain WB Hôte: Lapin Polyclonal unconjugated
-
-
Indications d'application
-
Immunohistochemistry: Paraffin embedded Human Brain (Cerebellum) and Heart. Recommended concentration: 2.5 μg/mL.
Western Blot: Approx. 38 kDa band observed in Human Brain (Cerebellum) lysates (calculated MW of 37.2 kDa according to NP_005661.1). Recommended concentration: 0.1-0.3 μg/mL. Primary incubation was 1 hour.
Peptide ELISA: antibody detection limit dilution 1:16000.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5 mg/mL
-
Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Minimize freezing and thawing.
-
Stock
- -20 °C
-
Stockage commentaire
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
-
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
-
Autre désignation
- EPM2A
-
Sujet
- Epilepsy, progressive myoclonus type 2, Lafora disease (laforin), laforin, EPM2A, epilepsy, progressive myoclonus type 2A, Lafora disease (laforin), EPM2, MELF
-
ID gène
- 7957, 13853, 680683
-
NCBI Accession
- NP_005661
-
Pathways
- Cellular Glucan Metabolic Process
Antigène
-
